General OLIVEDA Olive

OLIVEDA in Munich Hotel Bayerischer Hof with OLIVEDA beauty Ambassador Barbara Becker presents the new product design on the 15.10.2013, Bayerischer Hof in Munich solemnly invited the OLIVEDA cosmetics brand, to their first launch party at the five-star hotel. In addition to OLIVEDA founder Thomas Lommel and brand Ambassador Barbara Becker celebrated with 200 invited guests from business, culture, media, and the Munich society. Barbara Becker’s eldest son was responsible for the musical accompaniment of the evening: DJ Knowa alias Noah Becker. New product design reason for the festive occasion was the new design of the OLIVEDA products. All bottles, jars, and donors were given a more modern packaging and a cooler look.

The previous Green has given way to a fine clear white and the labels were consistent, simple and elegant design. The new designs in the Mediterranean-decorated ambience of luxury hotels were presented. A real olive grove of about a hundred-year-old mountain olive tree was rebuilt and received the guests of natural cosmetics with green, faithful place red carpet. Barbara Becker, OLIVEDA brand Ambassador a superbly glamorous occasion to introduce the Ambassador officially to the press. Barbara Becker, who was looking for a new, innovative natural cosmetics for the care of their skin, was alerted by her dermatologist to OLIVEDA. She received so many compliments after the application of friends and was so excited by the bright fresh skin result that she bought then equal 30 products in KDeWe Berlin for themselves. From personal conviction and initiative she contacted OLIVEDA Managing Director Thomas Lommel and suggested a collaboration at a meeting.

For the first time I got spontaneous”want to put my name behind a cult beauty brand, she says. Thomas Lommel hadn’t thought originally that a cooperation with a celebrity, but of course not long to ask. On the garden terrace of the Bavarian court hotels she could present personally their favorite products, which with the elixir of the olive tree as a main ingredient Include an anti-aging effect. This Elixir is the beauty secret of OLIVEDA and Barbara Becker and is extracted from the olive leaf in a unique and highly complex biotechnology process. An innovative characteristic, from which the guests then home personally could convince themselves after receiving the goodie bags. Contact: OLIVEDA Switzerland AG Thomas Lommel Aesche suburb 71, CH-4051 Basel Tel.: + 41 61 225 42 40 E-Mail: General OLIVEDA, headquartered in Switzerland, was founded by Thomas Lommel. The natural cosmetic products are manufactured in pure handwork and based on the fresh juice of the olive leaf according to ancient Klosterrezepturen from the Mediterranean area.

Powerful Enzymes

Start research cooperation Henkel Henkel and c-LEcta and c-LEcta have started a cooperation in new enzymes to the development of more sustainable detergent. The cooperation partners focus on even better removing stubborn stains that are especially relevant for consumers. In the joint research project identified and improved c-LEcta suitable enzymes by using their proprietary technology. Henkel checks based on his extensive experience in the development of detergent enzymes and formulations which ingredients are best suitable for better stain removal after a wash cycle. Enzymes are established components of modern detergents.

It is that detergent already at low temperatures efficiently remove a variety of stains to a considerable extent the merit of enzymes. In addition, they contribute to the preservation of tissues in the washing process. Through continuously improved enzymes, detergents can now make an important contribution to sustainability particularly energy – and resource-friendly formulations. Our goal is to enable the Consumer products to offer, showing a better performance at a lower ecological footprint”, says Prof. Dr.

Thomas Muller cherry, Corporate Senior Vice President R & D and supply chain laundry & home care at Henkel. We have decided with c-LEcta for a partner who has a high level of expertise for the development of process-optimised enzymes and clearly focused on delivering market-ready solutions. We are convinced that better enzymes to make a decisive contribution to the development of innovative detergent because they combine a high washing performance with the highest sustainability standards.”we are delighted to work with a strong partner like Henkel, and to contribute to develop sustainable detergent” added Dr. Marc Struhalla, co-founder and CEO of c-LEcta. We have already shown in various collaborations that the enzyme variety of our Biodiversitatssammlung together with our efficient technologies of engineering-valuable building blocks for the development of Bio-catalytic solutions are showing outstanding performance in challenging processes. We also present already great success in the development of products that can be integrated directly into the processes of our customers.” Henkel operates worldwide with leading brands and technologies in the three business segments of laundry & home care, beauty care, and adhesive technologies. The 1876 founded company holds leading global market positions in the consumer and industrial business with around 47,000 employees and famous brands such as Persil, Schwarzkopf or Loctite. In the fiscal year 2012, Henkel scored a turnover of 16.510 million and an adjusted operating profit of 2.335 million. Henkel preferred shares are listed on the DAX. c-LEcta is a specialist of in industrial biotechnology and develops customized enzymes and microbial production strains for sustainable and economical industrial processes. The Leipzig-based company covers with the discovery of new enzymes, whose engineering as well as the commercial production of specialized enzymes and tribes from a wide range of the value chain. Academic excellence combined with profound commercial and regulatory expertise allows it to bring innovative and competitive organic processes up to the scale of the product.

PSA Tumors

Proteins from semen as a potential source of information provide information. Prostate cancer is the second most common cancer of men worldwide. But long since not all prostate cancer is associated with a poor prognosis, which requires immediate intervention. There is, therefore, a major challenge to the diagnosis of prostate cancer, to distinguish between aggressive non-aggressive tumors. Currently, but still no procedure provides the necessary security. Scientists of the Urology Clinic of the University Hospital Leipzig AoR (www.urologie.uniklinikum-leipzig.de) have identified ejaculate as a potential source of information for detecting aggressive prostate tumors in cooperation with the Hanoverian biotechnology company of mosaiques diagnostics (www.mosaiques-diagnostics.com). Now, the results of their study were published in the current issue of the prestigious journal PLoS one: article/info%3Adoi%2F10.1371%2Fjournal.pone.0067514 In the study were using a special protein-analysis of ejaculate first specific markers for the diagnosis of Prostate cancer are identified. In a further step, the scientists succeeded in identifying 11 protein marker for the first time allow a distinction between the aggressive form of prostate cancer and a slowly growing tumor.

With a sensitivity of 80% and a specificity of 82%, protein analysis in the ejaculate allows a very high reliability in the differentiation of the tumor stage. Although in this respect still no real alternative to the tissue extraction from the prostate, the results of our study are very promising and could enable also a clear recommendation of the therapy in the future in addition to a specific diagnosis”, summarizes Dr. Neuhaus the results of the study. So far a combination of PSA test (prostate specific antigen), palpation, number of positive samples and the determination of the so-called Gleason value was used after the removal of tissue, to identify aggressive prostate tumors. However, slightly elevated PSA levels between 4 and 10 ng/ml and moderate show the majority of the discovered tumors Gleason values between 6 and 7, which greatly complicates a treatment decision. Tissue sampling be carried out to determine the value of the Gleason invasive, ejaculate, however, can be easily and without intervening measures to win. A clear added value on our way to more and more patient-friendly Diagnostics”, explains Dr. Eric Schiffer mosaiques Diagnostics.

Reference Neuhaus J, Schiffer E, Wilcke P, Bauer HW, Leung H, Siwy Ulrici W, p U, J, LC, Horn Santana J seminal plasma as a source of prostate cancer peptide biomarker candidates for detection of indolent and advanced disease PLoS ONE 8(6): e67514. DOI:10.1371/journal.Pone.0067514 about mosaiques diagnostics: A leading biotech company in the area of clinical analysis of protein in the urine (UPA), mosaiques diagnostics recognized cooperation partner of renowned university hospitals all over the world is. The UPA test is subject to over 60 multicenter studies, including several EU consortia. 155 Publications in high-ranking, international journals have appeared to a few years. Under the diagnostic tests for different diseases on the market the brand name DiPat (www.diapat.de) are available. They are suitable in particular for the early detection of chronic kidney disease (CKD), such as the diabetic nephropathy (DN), as well as for coronary heart disease (CHD). Thus, the protein analysis is predestined to implement evidence-based, personalized treatments in patients with diabetes mellitus effectively.

Asian Productivity Organization

“” President of the Republic of China (Taiwan) Ma Ying-jeou of the President of the Republic of China (Taiwan), Ma Ying-jeou, urges ‘green’ productivity said during the inauguration of the Asian Productivity Organization’s (APO) Center of excellence on green productivity “in Taipei City, that the process for Taiwan towards a low-carbon and green energy” company could be painful, but through joint efforts and hard work could be mastered. “Ma said: we need to increase our green productivity under the premise that will reduce energy consumption, without thereby missing the national productivity goals.” Taiwan founded in 1955 the China Productivity Center”and founding member of APO was in 1961 and experience history looks back in this respect on a long. The APO has helped its members to increase productivity in the industry, agriculture and services sectors. Its focus is on green productivity in the past Years is in line with Taiwan’s promotion of low-carbon and green energy”policy. According to Ma Ying-jeou of Taiwan Government’s policy focuses on six key emerging industries: use of green energy sources, biotechnology, tourism, health and care, high-performance agriculture and cultural innovation.

More four emerging smart industries cloud computing, intelligent electric vehicles, smart ecological construction and industrial patent applications have been added to the green industry wave. Ma said that Taiwan its carbon emissions last year reduced millions of tons to 6.1 and planted at the same time 61,000 trees. The environmental protection administration to new Taipei, Taichung, Tainan and Yilan in low-carbon cities by 2014 and convert carbon Islands Penghu and Kinmen. An extension of the plan up to 2020 includes Northern, Central, southern and Eastern parts of Taiwan and is a testament to the commitment of Taiwan with regard to the reduction of pollutants. In the last year, Taiwan has produced 3.38 million tonnes of waste.

Compared to the peak year of 1998, which means a reduction of 62%. Meanwhile, 42% recycling has increased in 2007 to 65% in 2012. The Government has saved also, electricity 20 billion kilowatt hours since the introduction of the economic plan five years ago. The APO is one of the few international organizations in which Taiwan under its official title Republic of China (Taiwan) is member.

PSA Cancer

Proteins from semen as a potential source of information provide information. Prostate cancer is the second most common cancer of men worldwide. But long since not all prostate cancer is associated with a poor prognosis, which requires immediate intervention. There is, therefore, a major challenge to the diagnosis of prostate cancer, to distinguish between aggressive non-aggressive tumors. Currently, but still no procedure provides the necessary security. Scientists of the Urology Clinic of the University Hospital Leipzig AoR (www.urologie.uniklinikum-leipzig.de) have identified ejaculate as a potential source of information for detecting aggressive prostate tumors in cooperation with the Hanoverian biotechnology company of mosaiques diagnostics (www.mosaiques-diagnostics.com).

Now, the results of their study were published in the current issue of the prestigious journal PLoS one: article/info%3Adoi%2F10.1371%2Fjournal.pone.0067514 In the study were using a special protein-analysis of ejaculate first specific markers for the diagnosis of Prostate cancer are identified. In a further step, the scientists succeeded in identifying 11 protein marker for the first time allow a distinction between the aggressive form of prostate cancer and a slowly growing tumor. With a sensitivity of 80% and a specificity of 82%, protein analysis in the ejaculate allows a very high reliability in the differentiation of the tumor stage. Although in this respect still no real alternative to the tissue extraction from the prostate, the results of our study are very promising and could enable also a clear recommendation of the therapy in the future in addition to a specific diagnosis”, summarizes Dr. Neuhaus the results of the study. So far a combination of PSA test (prostate specific antigen), palpation, number of positive samples and the determination of the so-called Gleason value was used after the removal of tissue, to identify aggressive prostate tumors. However, slightly elevated PSA levels between 4 and 10 ng/ml and moderate show the majority of the discovered tumors Gleason values between 6 and 7, which greatly complicates a treatment decision.

Tissue sampling be carried out to determine the value of the Gleason invasive, ejaculate, however, can be easily and without intervening measures to win. A clear added value on our way to more and more patient-friendly Diagnostics”, explains Dr. Eric Schiffer mosaiques Diagnostics. Reference Neuhaus J, Schiffer E, Wilcke P, Bauer HW, Leung H, Siwy Ulrici W, p U, J, LC, Horn Santana J seminal plasma as a source of prostate cancer peptide biomarker candidates for detection of indolent and advanced disease PLoS ONE 8(6): e67514. DOI:10.1371/journal.Pone.0067514 about mosaiques diagnostics: A leading biotech company in the area of clinical analysis of protein in the urine (UPA), mosaiques diagnostics recognized cooperation partner of renowned university hospitals all over the world is. The UPA test is subject to over 60 multicenter studies, including several EU consortia. 155 Publications in high-ranking, international journals have appeared to a few years. Under the diagnostic tests for different diseases on the market the brand name DiPat (www.diapat.de) are available. They are suitable in particular for the early detection of chronic kidney disease (CKD), such as the diabetic nephropathy (DN), as well as for coronary heart disease (CHD). Thus, the protein analysis is predestined to implement evidence-based, personalized treatments in patients with diabetes mellitus effectively. More tests for the early detection of stenosis of renal pelvis outlet in newborn (UPJO), acute Graft-versus-host disease (GvHD) in allogeneic stem cell transplantation (SCT) and bile duct cancer, bladder and prostate cancer are also already available.

Haemostaseology

The accolade for the DiPat protein pattern analysis the stem cell transplant, the transmission of blood-forming stem cells from the bone marrow or blood from healthy donors, often represents the only way to cure Leukemia patients. The acute Graft-versus-host disease (GvHD) is one of the life-threatening complications of the transplant. GvHD occurs at approximately 35% to 85% of transplanted patients. This graft-versus host-reaction which are transmitted immune cells of the donor (graft) against the body of the receiver (host) and this attack. The clinical symptoms of this reaction is evident primarily in skin, liver and intestines.

The early recognition of this rejection is crucial to treat life-threatening complications. So far, the diagnosis was based mainly on the medical assessment of the clinical symptoms and the histological assessment of surgically removed tissue of the affected organs. Scientists of the biotechnology company mosaiques diagnostics (www.mosaiques-diagnostics.com) now in a prospective, multicenter study with the clinic for Haematology, Haemostaseology and Oncology and stem cell transplantation at the medical school Hannover (MHH, 250.html) noticed: the innovative urine-protein analysis diagnosed GvHD already 14 days before the first clinical symptoms, and objectively measurable. Even more. The protein pattern analysis provides information about the risk of GvHD present, to develop towards the critical, life-threatening grade III and IV in addition from the outset. (Grade I and II are quite desirable from a therapeutic perspective.) In the framework of the renowned in the journal leukemia”published study (www.nature.com/ leu/journal/vaop/naam/abs/leu2013210a.html) stammzelltransplantierten with 423 Leukemia patients from five transplant centers continue to impressively showed that the protein pattern analysis in addition to the first measurable early ster ID is ultimately even a best Therapeutic choice and – all degrees of severity enables secure GvHD-monitoring and control of measures initiated. This non-invasive method enables a targeted therapy for the first time and prevents life-threatening skin, liver and intestinal complications,”Dr. Jochen Metzger summarizes mosaiques Diagnostics.